



**Publikationen/Abstracts, Co-Autorenschaften** (Stand: 09/2023)

**Prof. Dr. med. Michael Braun,**  
**Chefarzt Hauptabteilung Gynäkologie**  
**Leiter Interdisziplinäres Brustzentrum**

*De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.*

Harbeck N, Nitz UA, Christgen M, Kümmel S, Braun M, Schumacher C, Potenberg J, Tio J, Aktas B, Forstbauer H, Grischke EM, Scheffen I, Malter W, von Schumann R, Just M, Zu Eulenburg C, Biehl C, Kolberg-Liedtke C, Deurloo R, de Haas S, Jó?wiak K, Hauptmann M, Kates R, Graeser M, Wuerstlein R, Kreipe HH, Gluz O; WSG-ADAPT investigators.

J Clin Oncol. 2023 Aug 1;41(22):3796-3804. doi: 10.1200/JCO.22.01816. Epub 2023 Feb 21. PMID: 36809046 Clinical Trial.

*Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial.*

Gluz O, Kuemmel S, Nitz U, Braun M, Lüdtke-Heckenkamp K, von Schumann R, Darsow M, Forstbauer H, Potenberg J, Uleer C, Grischke EM, Aktas B, Schumacher C, Zu Eulenburg C, Kates R, Jó?wiak K, Graeser M, Wuerstlein R, Baehner R, Christgen M, Kreipe HH, Harbeck N.

Ann Oncol. 2023 Jun;34(6):531-542. doi: 10.1016/j.annonc.2023.04.002.

*Adjuvant Therapy for Elderly Breast Cancer Patients after Breast-Conserving Surgery: Outcomes in Real World Practice*

Paul Rogowski, Stephan Schönecker, Dinah Konnerth, Annemarie Schäfer, Montserrat Pazos, Aurélie Gaasch, Maximilian Niyazi, Edwin Boelke, Christiane Matuschek, Jan Haussmann, Michael Braun, Martin Pölcher, Rachel Würstlein, Nadia Harbeck, Claus Belka, Stefanie Corradini.

Cancers (Basel). 2023 Apr 17;15(8):2334. doi: 10.3390/cancers15082334.

*Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT-HER2+/HR- trial.*

Graeser M, Gluz O, Biehl C, Ulbrich-Gebauer D, Christgen M, Palatty J, Kuemmel S, Grischke EM, Augustin D, **Braun M**, Potenberg J, Wuerstlein R, Krauss K, Schumacher C, Forstbauer H, Reimer T, Stefek A, Fischer HH, Pelz E, Zu Eulenburg C, Kates R, Ni H, Kolberg-Liedtke C, Feuerhake F, Kreipe HH, Nitz U, Harbeck N.

Clin Cancer Res. 2022 Nov 28;CCR-22-1587. doi: 10.1158/1078-0432.CCR-22-1587. Online ahead of print.

*Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.*

Loibl S, Schneeweiss A, Huober J, **Braun M**, Rey J, Blohmer JU, Furlanetto J, Zahm DM, Hanusch C, Thomalla J, Jackisch C, Staib P, Link T, Rhiem K, Solbach C, Fasching PA, Nekljudova V, Denkert C, Untch M; GBG and AGO-B.

Ann Oncol. 2022 Nov;33(11):1149-1158. doi: 10.1016/j.annonc.2022.07.1940. Epub 2022 Aug 9.

*Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.*

Kolberg-Liedtke C, Feuerhake F, Garke M, Christgen M, Kates R, Grischke EM, Forstbauer H, **Braun M**, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kuemmel S, Wuerstlein R, Graeser M, Nitz U, Kreipe H, Gluz O, Harbeck N.

Breast Cancer Res. 2022 Sep 2;24(1):58. doi: 10.1186/s13058-022-01552-w.

*De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Impact of molecular markers and survival analysis of the WSG-ADAPT-TN trial.*

Gluz O, Nitz U, Kolberg-Liedtke C, Prat A, Christgen M, Kuemmel S, Mohammadian MP, Gebauer D, Kates R, Paré L, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Wuerstlein R, Graeser M, Pelz E, J6?wiak K, Zu Eulenburg C, Kreipe HH, Harbeck N. Clin Cancer Res. 2022 Jul 7; ccr.22.0482. doi: 10.1158/1078-0432.CCR-22-0482. Online ahead of print.  
PMID: 35797219

*Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2-Early Breast Cancer.*

Nitz UA, Gluz O, Kümmel S, Christgen M, Braun M, Aktas B, Lüdtke-Heckenkamp K, Forstbauer H, Grischke EM, Schumacher C, Darsow M, Krauss K, Nuding B, Thill M, Potenberg J, Uleer C, Warm M, Fischer HH, Malter W, Hauptmann M, Kates RE, Gräser M, Würstlein R, Shak S, Baehner F, Kreipe HH, Harbeck N; West German Study Group. J Clin Oncol. 2022 Apr 11; JCO2102759. doi: 10.1200/JCO.21.02759. Online ahead of print.  
PMID: 35404683

*De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.*

Nitz U, Gluz O, Graeser M, Christgen M, Kuemmel S, Grischke EM, Braun M, Augustin D, Potenberg J, Krauss K, Schumacher C, Forstbauer H, Reimer T, Stefek A, Fischer HH, Pelz E, Zu Eulenburg C, Kates R, Wuerstlein R, Kreipe HH, Harbeck N; WSG-ADAPT investigators. Lancet Oncol. 2022 May; 23(5):625-635. doi: 10.1016/S1470-2045(22)00159-0. Epub 2022 Apr 8.  
PMID: 35405088 Clinical Trial.

*Validation of the 21-Gene Recurrence Score Assay in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer and 0 to 3 Positive Lymph Nodes: Risk Pattern and Outcomes on a Community Level.*

Michael Braun Antonia Kriegmair Nina Szeterlak Anne Andrulat Simone Schrodi Monika Kriner Claus Hanusch Moritz Hamann Oliver Stoetzer Martin Pölcher Breast Care 2022;17:288–295 · 10.1159/000521096

*TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.*

Grote I, Bartels S, Kandt L, Bollmann L, Christgen H, Gronewold M, Raap M, Lehmann U, Gluz O, Nitz U, Kuemmel S, Zu Eulenburg C, Braun M, Aktas B, Grischke EM, Schumacher C, Luedtke-Heckenkamp K, Kates R, Wuerstlein R, Graeser M, Harbeck N, Christgen M, Kreipe H. Cancer Med. 2021 Dec; 10(23):8581-8594. doi: 10.1002/cam4.4376. Epub 2021 Nov 14.

*Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort.*

Schrodi S, Braun M, Andrulat A, Harbeck N, Mahner S, Kiechle M, Klein E, Schnelzer A, Schindlbeck C, Bauerfeind I, Schubert-Fritschle G, Nekljudova V, Mayr D, Weichert W, Denkert C, Loibl S, Engel J. Ann Oncol. 2021 Nov; 32(11):1410-1424. doi: 10.1016/j.annonc.2021.08.1988. Epub 2021 Aug 20.

*Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.*

Harbeck N, von Schumann R, Kates RE, Braun M, Kuemmel S, Schumacher C, Potenberg J, Malter W, Augustin D, Aktas B, Forstbauer H, Tio J, Grischke EM, Biehl C, Liedtke C, De Haas SL, Deurloo R, Wuerstlein R, Kreipe HH, Gluz O. Cancers (Basel). 2021 Sep 29; 13(19):4884. doi: 10.3390/cancers13194884.

• *Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer.*

Helbrich H, Braun M, Hanusch C, Mueller G, Falk H, Flondor R, Harbeck N, Hermelink K, Wuerstlein R, Keim S, Neufeld F, Steins-Loeber S, Haertl K.  
Breast Cancer Res Treat. 2021 Jul;188(2):351-359. doi: 10.1007/s10549-021-06195-7. Epub 2021 Mar 31

*Post-Neoadjuvant Gemcitabine and Cisplatin with Regional Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute Experience.*

Stoetzer O, Di Gioia D, Issels RD, Abdel-Rahman S, Mansmann U, Lindner LH, Gluz O, Würstlein R, Braun M, Hamann M, Edler von Koch F, Harbeck N, Salat C.  
Breast Care (Basel). 2021 Apr;16(2):173-180. doi: 10.1159/000507473. Epub 2020 May 12.

*The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials*

Graeser G, Harbeck N, Gluz O, Würstlein R, Zu Eulenburg C, Schumacher C, Grischke E, Forstbauer H, Dimpfl M, Braun M, Christgen M, Kreipe HH, Potenberg J, von Schumann R, Aktas B, Kolberg-Liedtke C, Kümmel S, Nitz U  
Breast. 2021 Jun 14;59:58-66. doi: 10.1016/j.breast.2021.06.001.

*Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.*

Graeser M, Feuerhake F, Gluz O, Volk V, Hauptmann M, Jozwiak K, Christgen M, Kuemmel S, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kolberg-Liedtke C, Kates R, Wuerstlein R, Nitz U, Kreipe HH, Harbeck N.  
J Immunother Cancer. 2021 May;9(5):e002198. doi: 10.1136/jitc-2020-002198.

*Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials.*

Graeser M, Schrading S, Gluz O, Strobel K, Herzog C, Umutlu L, Frydrychowicz A, Rjosk-Dendorfer D, Würstlein R, Culemann R, Eulenburg C, Adams J, Nitzsche H, Prange A, Kümmel S, Grischke EM, Forstbauer H, Braun M, Potenberg J, von Schumann R, Aktas B, Kolberg-Liedtke C, Harbeck N, Kuhl CK, Nitz U.  
Breast Cancer Res. 2021 Mar 18;23(1):36. doi: 10.1186/s13058-021-01413-y.

*Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer.*

Pölcher M, Braun M, Tischitz M, Hamann M, Szeterlak N, Kriegmair A, Brambs C, Becker C, Stoetzer O. Arch Gynecol Obstet. 2021 Feb 14. doi: 10.1007/s00404-021-05996-x. Online ahead of print.

*Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.*

Graeser M, Schrading S, Gluz O, Strobel K, Würstlein R, Kümmel S, Schumacher C, Grischke EM, Forstbauer H, Braun M, Christgen M, Adams J, Nitzsche H, Just M, Fischer HH, Aktas B, Potenberg J, von Schumann R, Kolberg-Liedtke C, Harbeck N, Kuhl CK, Nitz U. Int J Cancer. 2021 Feb 3;148(10):2614-27. doi: 10.1002/ijc.33495.

*The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer.*

Nitz U, Gluz O, Kreipe HH, Christgen M, Kuemmel S, Baehner FL, Shak S, Aktas B, Braun M, Lütke-Heckenkamp K, Forstbauer H, Grischke EM, Nuding B, Darsow M, Schumacher C, Krauss K, Malter W, Thill M, Warm M, Wuerstlein R, Kates RE, Harbeck N.  
Ther Adv Med Oncol. 2020 Nov 23;12:1758835920973130.

*Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute Experience.*

Stoetzer O, Di Gioia D, Issels R, D, Abdel-Rahman S, Mansmann U, Lindner L, H, Gluz O, Würstlein R, Braun M, Hamann M, Edler von Koch F, Harbeck N, Salat C  
Breast Care 2020. doi: 10.1159/000507473.

*Sentinel lymph node mapping with indocyanine green compared to blue dye tracer in gynecologic malignancies-A single center experience of 218 patients*

M Pölcher, S Matz, M Braun, C Brambs, M Beer, M Hamann  
J Surg Oncol. 2020 Dec 17. doi: 10.1002/jso.26338. Online ahead of print.

*Heart sparing radiotherapy in breast cancer: the importance of baseline cardiac risks.*

Gaasch A, Schönecker S, Simonetto C, Eidemüller M, Pazos M, Reitz D, Rottler M, Freislederer P, Braun M, Würstlein R, Harbeck N, Niyazi M, Belka C, Corradini S.  
Radiat Oncol. 2020 May 24;15(1):117. doi: 10.1186/s13014-020-01520-8.

*Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.*

Gluz O, Kolberg-Liedtke C, Prat A, Christgen M, Gebauer D, Kates R, Paré L, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kuemmel S, Wuerstlein R, Pelz E, Nitz U, Kreipe HH, Harbeck N.  
Int J Cancer. 2020 Jan 1;146(1):262-271. doi: 10.1002/ijc.32488. Epub 2019 Jun 19.

*Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019).*

Lüftner D, Bauerfeind I, Braun M, Brucker SY, Fasching PA, Felberbaum R, Hagemann F, Haidinger R, Harbeck N, Höning A, Huober J, Jackisch C, Kolberg HC, Kolberg-Liedtke C, Kühn T, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thomssen C, Untch M, Wuerstlein R, Thill M.  
Breast Care (Basel). 2019 Oct;14(5):315-324. doi: 10.1159/000502603. Epub 2019 Sep 17. Review.

*Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019).*

Untch M, Thomssen C, Bauerfeind I, Braun M, Brucker SY, Felberbaum R, Hagemann F, Haidinger R, Höning A, Huober J, Jackisch C, Kolberg HC, Kolberg-Liedtke C, Kühn T, Lüftner D, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thill M, Wuerstlein R, Fasching PA, Harbeck N.  
Geburtshilfe Frauenheilkd. 2019 Jun;79(6):591-604. doi: 10.1055/a-0897-6457. Epub 2019 Jun 14.

*Quality of life in breast cancer patients and surgical results of immediate tissue expander/implant-based breast reconstruction after mastectomy.*

Hamann M, Brunnbauer M, Scheithauer H, Hamann U, Braun M, Pölcher M.  
Arch Gynecol Obstet. 2019 Aug;300(2):409-420. doi: 10.1007/s00404-019-05201-0. Epub 2019 May 29.

*Does deep inspiration breath-hold prolong life? Individual risk estimates of ischaemic heart disease after breast cancer radiotherapy.*

Simonetto C, Eidemüller M, Gaasch A, Pazos M, Schönecker S, Reitz D, Käab S, Braun M, Harbeck N, Niyazi M, Belka C, Corradini S.  
Radiother Oncol. 2019 Feb;131:202-207. doi: 10.1016/j.radonc.2018.07.024. Epub 2018 Aug 7.

*Individual Factors Contributing to Nausea in First-Time Chemotherapy Patients: A Prospective Cohort Study.*

Meissner K, Talsky N, Olliges E, Jacob C, Stötzer OJ, Salat C, Braun M, Flondor R.  
Front Pharmacol. 2019 Apr 25;10:410. doi: 10.3389/fphar.2019.00410. eCollection 2019.

*Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: an observational study.*

Rogowski P, Schönecker S, Pazos M, Reitz D, Braun M, Pölcher M, Hanusch C, Wuerstlein R, Harbeck N, Mahner S, Belka C, Corradini S.  
Strahlenther Onkol. 2019 Apr;195(4):289-296. doi: 10.1007/s00066-018-1337-8. Epub 2018 Jul 25.

*Mastectomy or Breast-Conserving Therapy for Early Breast Cancer in Real-Life Clinical Practice: Outcome Comparison of 7565 Cases.*

Corradini S, Reitz D, Pazos M, Schönecker S, Braun M, Harbeck N, Matuschek C, Bölke E, Ganswindt U, Alongi F, Niyazi M, Belka C.  
Cancers (Basel). 2019 Jan 31;11(2). pii: E160. doi: 10.3390/cancers11020160.

*Recent Developments in Radiation Oncology: An Overview of Individualised Treatment Strategies in Breast Cancer.*

Pazos M, Schönecker S, Reitz D, Rogowski P, Niyazi M, Alongi F, Matuschek C, Braun M, Harbeck N, Belka C, Corradini S.  
Breast Care (Basel). 2018 Aug;13(4):285-291. doi: 10.1159/000488189. Epub 2018 May 24. Review

*Endometrial cancer-how many patients could benefit from sentinel lymph node dissection?*

Brugger S, Hamann M, Mosner M, Beer M, Braun M, Pölcher M.  
World J Surg Oncol. 2018 May 17;16(1):95. doi: 10.1186/s12957-018-1392-8

*Role of postoperative radiotherapy in reducing ipsilateral recurrence in DCIS: an observational study of 1048 cases.*

Corradini S, Pazos M, Schönecker S, Reitz D, Niyazi M, Ganswindt U, Schrodi S, Braun M, Pölcher M, Mahner S, Harbeck N, Engel J, Belka C.  
Radiat Oncol. 2018 Feb 9;13(1):25. doi: 10.1186/s13014-018-0964-7.

*Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.*

Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Bangemann N, Lindner C, Kuemmel S, Clemens M, Potenberg J, Staib P, Kohls A, von Schumann R, Kates R, Kates R, Schumacher J, Wuerstlein R, Kreipe HH, Harbeck N. J Natl Cancer Inst. 2017 Dec 8. doi: 10.1093/jnci/djx258. [Epub ahead of print] PMID: 29228315

*De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.*

Nitz UA, Gluz O, Christgen M, Grischke EM, Augustin D, Kuemmel S, Braun M, Potenberg J, Kohls A, Krauss K, Stefek A, Schumacher C, Forstbauer H, Reimer T, Fischer H, Liedtke C, Wuerstlein R, Schumacher J, Kates R, Kreipe H, Harbeck N; West-German Study Group (WSG)-ADAPT

Investigators. *Ann Oncol*. 2017 Nov 1;28(11):2768-2772. doi: 10.1093/annonc/mdx494. PMID: 28945833

*Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients.*

Hermelink K, Bühner M, Sckopke P, Neufeld F, Kaste J, Voigt V, Münzel K, Wuerstlein R, Ditsch N, Hellerhoff K, Rjosk-Dendorfer D, Braun M, von Koch FE, Härtl K, Hasmüller S, Bauerfeind I, Debus G, Herschbach P, Mahner S, Harbeck N.  
*J Natl Cancer Inst*. 2017 Oct 1;109(10)

*De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET*

Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, von Schumann R, Liedtke C, Grischke EM, Schumacher J, Wuerstlein R, Kreipe HH, Nitz UA  
*Journal Clin Oncol*. 2017 Jul 6 [Epub ahead of print]

*Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry.*

Hölzel D, Eckel R, Bauerfeind I, Baier B, Beck T, Braun M, Ettl J, Hamann U, Kiechle M, Mahner S, Schindlbeck C, de Waal J, Harbeck N, Engel J.  
*Journal Cancer Res Clin Oncol*. 2017 Apr 20. [Epub ahead of print]

*Survival of de novo stage IV breast cancer patients over three decades.*

Hölzel D, Eckel R, Bauerfeind I, Baier B, Beck T, Braun M, Ettl J, Hamann U, Harbeck N, Kiechle M, Mahner S, Schindlbeck C, de Waal J, Engel J  
*Journal Cancer Res Clin Oncol*. 2017 Mar;143(3):509-519

*Trends in use and outcome of postoperative radiotherapy following mastectomy: a population-based study.*

Corradini S, Bauerfeind I, Belka C, Braun M, Combs SE, Eckel R, Harbeck N, Hölzel D, Kiechle M, Niyazi M, Engel J  
(2016) *Journal Radiotherapy and Oncology* 2016 Sep 15. pii: SO167-8140(16)34282-7

*Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer.*

Kast K, Rhiem K, Wappenschmidt B, Hahnen E, Hauke J, Bluemcke B, Zarghooni V, Herold N, Ditsch N, Kiechle M, Braun M, Fischer C, Dikow N, Schott S, Rahner N, Niederacher D, Fehm T, Gehrig A, Mueller-Reible C, Arnold N, Maass N, Borck G, de Gregorio N, Scholz C, Auber B, Varon-Manteeva R, Speiser D, Horvath J, Lichey N, Wimberger P, Stark S, Faust U, Weber BH, Emons G, Zachariae S, Meindl A, Schmutzler RK, Engel C; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC)  
*J Med Genet*. 2016 Jul;53(7):465-71

*• Who may benefit from preoperative breast MRI? A single-center analysis of 1102 consecutive patients with primary breast cancer.*

Debald M, Abramian A, Nemes L, Döbler M, Kaiser C, Keyver-Paik MD, Leutner C, Höller T, Braun M,

Kuhl C, Kuhn W, Schild HH  
Breast Cancer Res Treat. 2015 Oct;153(3):531-7

*Elucidating Pretreatment Cognitive Impairment in Breast Cancer Patients: The Impact of Cancer-related Post-traumatic Stress.*

Hermelink K, Voigt V, Kaste J, Neufeld F, Wuerstlein R, Bühner M, Münzel K, Rjosk-Dendorfer D, Grandl S, Braun M, von Koch FE, Härtl K, Hasmüller S, Bauerfeind I, Debus G, Herschbach P, Harbeck N  
J Natl Cancer Inst. 2015 Apr 16;107(7)

*Stellenwert minimal-invasiver Technik: verdrängt die laparoskopische Hysterektomie die vaginale Hysterektomie?*

S Brugger, U Hamann, W Alberti, N von Obernitz, M Braun, M Pölcher  
Geburtshilfe und Frauenheilkunde 09/2014; 74(S 01)

*Staging of Primary Breast Cancer Is not Indicated in Asymptomatic Patients with Early Tumor Stages.*

Debald M, Wolfgarten M, Kreklau P, Abramian A, Kaiser C, Höller T, Leutner C, Keyver-Paik MD, Braun M, Kuhn W  
Oncol Res Treat. 2014;37(7-8):400-5

*Evaluation of e-cadherin, ki-67 and lymphatic vessel invasion in abdominal metastases of human breast cancer.*

Debald M, Kaiser C, Abramian A, Schildhaus HU, Locher P, Wolfgarten M, Kuhn W, Braun M  
Anticancer Res. 2013 May;33(5):1971-5

*Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNase, cytokeratin-18 fragments and survivin.*

Stoetzer OJ, Fersching DM, Salat C, Steinkohl O, Gabka CJ, Hamann U, Braun M, Feller AM, Heinemann V, Siegele B, Nagel D, Holdenrieder S  
Cancer Lett. 2013 Apr 21. pii: S0304-3835(13)00347-9

*Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.*

Stoetzer OJ, Fersching DM, Salat C, Steinkohl O, Gabka CJ, Hamann U, Braun M, Feller AM, Heinemann V, Siegele B, Nagel D, Holdenrieder S  
Tumour Biol. 2013 Feb;34(1):81-90

*Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?*

Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun M, Debald M, Kuhn W, Schild HH  
EPMA J. 2013 Feb 19;4(1)

*Pharmaceutical care for patients with breast and ovarian cancer.*

Liekweg A, Westfeld M, Braun M, Zivanovic O, Schink T, Kuhn W, Jaehde U  
Support Care Cancer. 2012 Nov;20(11):2669-77 IF:2,56

*Detection of lymphovascular invasion by d2-40 (podoplanin) immunoexpression in endometrial cancer.*

Weber SK, Sauerwald A, Pölcher M, Braun M, Debald M, Serce NB, Kuhn W, Brunagel-Walgenbach G, Rudlowski C  
Int J Gynecol Cancer. 2012 Oct;22(8):1442-8

*Identification of specific nuclear structural protein alterations in human breast cancer.*

Debald M, Franken S, Heukamp LC, Linke A, Wolfgarten M, Walgenbach KJ, Braun M, Rudlowski C, Gieselmann V, Kuhn W, Hartmann G, Walgenbach-Brünagel G  
J Cell Biochem. 2011 Nov;112(11):3176-84

*Potential Impact of Preoperative Magnetic Resonance Imaging of the Breast on Patient Selection for Accelerated Partial Breast Irradiation.*

Kühr M, Wolfgarten M, Stölzle M, Leutner C, Höller T, Schrading S, Kuhl C, Schild H, Kuhn W, Braun M  
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e541-6

*Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.*

Simons S, Ringsdorf S, Braun M, Mey UJ, Schwindt PF, Ko YD, Schmidt-Wolf I, Kuhn W, Jaehde U  
Support Care Cancer. 2011 Jul;19(7):1009-18

• *A Rare Complication Following Breast Implant Surgery: Capsular Contracture with a Cutaneous Silicone Fistula after Breast Reconstruction with Silicone Gel Implants.*

Walgenbach KJ, Kuhl C, Rudlowski C, Poelcher M, Sauerwald A, Walgenbach-Brünagel G, Kuhn W, Braun M  
Breast Care (Basel). 2011;6(1):51-53

*Noninvasive subcellular imaging in breast cancer risk assessment: construction of diagnostic windows.*

Yeghiazaryan K, Cebioglu M, Braun M, Kuhn W, Schild HH, Golubnitschaja O  
Personalized Med 2011, Vol. 8(3):321–330

*Increased detection of lymphatic vessel invasion by D2-40 (podoplanin) in early breast cancer: possible influence on patient selection for Accelerated Partial Breast Irradiation (APBI).*

M. Debald, M. Pölcher, U. Flucke, G. Walgenbach-Brünagel, K.J. Walgenbach, T. Höller, M. Wolfgarten, C. Rudlowski, R. Büttner, H. Schild, W. Kuhn, M. Braun  
Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1128-33

*Distinguishing medullary carcinoma of the breast from highgrade hormone receptor-negative invasive ductal carcinoma: an immunohistochemical approach.*

Flucke U, Flucke MT, Hoy L, Breuer E, Goebbels R, Rhiem K, Schmutzler R, Winzenried H, Braun M, Steiner S, Büttner R, Gevensleben H  
Histopathology. 2010 Jun;56(7):852-9

*Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma.*

Pölcher M, Braun M, Friedrichs N, Rudlowski C, Bercht E, Fimmers R, Sauerwald A, Keyver-Paik MD, Kübler K, Büttner R, Kuhn WC, Hernando JJ  
Cancer Immunol Immunother. 2010 Jun;59(6):909-19

*MRI-guided breast biopsy: influence of choice of vacuum biopsy system on the mode of biopsy of MRI-only suspicious breast lesions.*

Schrading S, Simon B, Braun M, Wardelmann E, Schild HH, Kuhl CK  
AJR Am J Roentgenol. 2010 Jun;194(6):1650-7

*Impact of the menstrual cycle on circulating cell-free DNA.*



Pölcher M, Rudlowski C, Friedrichs N, Mielich M, Höller T, Wolfgarten M, Kübler K, Büttner R, Kuhn W, Braun M  
Anticancer Res. 2010 Jun;30(6):2235-40

*Changes in Ki-67 Labelling Indices During Neoadjuvant Chemotherapy for Advanced Ovarian Cancer are Associated With Survival.*

Pölcher M., Friedrichs N., Rudlowski C., Fimmers R., Keyver-Paik M.D., Kübler K., Sauerwald A., Büttner R., Kuhn W., Braun M.  
Int J Gynecol Cancer. 2010 May;20(4):555-60

*In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer.*

Pölcher M, Rudlowski C, Friedrichs N, Mielich M, Höller T, Wolfgarten M, Kübler K, Büttner R, Kuhn W, Braun M  
Cancer Immunol Immunother. 2010 Jun;59(6):909-19. Epub 2010 Jan 20. BMC Cancer. 2010 Apr 13;10:137

*Prediction and Prognosis: Impact of Gene Expression Profiling in Personalized Treatment of Breast Cancer Patients.*

Mallmann M., Staratschek-Jox A., Rudlowski C., Braun M., Kuhn W., Schultze J.  
The EPMA Journal 2010 1;3:413-420

*Non-invasive Proteomics – thinking about personalized breast cancer screening and treatment.*

Debald M., Walgenbach-Brünagel G., Braun M.  
The EPMA Journal 2010 1;3:413-420

*Detection of lymphovascular invasion in vulvar cancer by D2-40 (podoplanin) as a predictor for inguinal lymph node metastases.*

M. Braun, E. Wardelmann, M. Debald, G. Walgenbach-Brunagel, T. Höller, M. Wolfgarten, A. Sauerwald, C. Rudlowski, R. Büttner, W. Kuhn, M. Pölcher  
Onkologie. 2009 Dec;32(12):732-8

*Neoadjuvant Chemotherapy With Carboplatin and Docetaxel in Advanced Ovarian Cancer – a Prospective Multicenter Phase 2 Trial (PRIMOVAR).*

M. Pölcher, S. Mahner, O. Ortmann, J. Hilfrich, M. Braun, W. Kuhn  
Oncol Rep. 2009 Sep;22(3):605-13

*Down-regulation of microfilament network-associated proteins in leukocytes of breast cancer patients: potential application to predictive diagnosis.*

M. Braun, M. Fountoulakis, I. Seidel, T. Höller, K. Yeghiazaryan, H. Schild, W. Kuhn and O. Golubnitschaja  
Cancer Genomics and Proteomics 2009; 6:31-40

*Cost-Cost Analysis Comparing an Anthracycline/Docetaxel Regime to CMF in Patients with Early Stage Breast Cancer.*

M. Braun, V. R. Jacobs, S. Wagenpfeil, D. Sattler, R. Bernard, W. Kuhn and A. Ihbe-Heffinger  
Onkologie 2009; 32:473-481

*Influence of preoperative MRI on the surgical management of patients with operable breast cancer.*

M. Braun, M. Pölcher, S. Schrading, O. Zivanovic, Th. Kowalski, U. Flucke, C. Leutner, T.-W. Park-

Simon, C. Rudlowski, W. Kuhn, C. K. Kuhl  
Breast Cancer Res. Treat 2008 Sep;111(1):179-87

*Magnetic resonance imaging in preoperative staging for breast cancer: pros and contras.*  
C. Kuhl, M. Braun  
Radiologe 2008 Apr;48(4):358-66

*Fertilitätsprotektion bei onkologischen Patientinnen: Kryobank Bonn – Beratung, Anwendung und die Bedeutung für die betroffene Frau.*  
M. Wollenschein, K. van der Ven, M. Montag, M. Braun, A. Rohde  
Geburtsh Frauenheilk 2008; 68: 262–267

*Cancer female patients with desire to have children: Significance of cryopreservation of the ovary tissues an example of Cryobank Bonn.*  
M. Wollenschein, M.M. Montag, K. van der Ven, M. Braun, A. Rohde  
Geburtsh Frauenheilk 2008; 68: 188-189

*Detection of lymphovascular invasion in early breast cancer by D2-40 (podoplanin): a clinically useful predictor for axillary lymph node metastases.*  
M. Braun, U. Flucke, M. Debold, G. Walgenbach-Bruenagel, K. J. Walgenbach, T. Höller, M. Pölcher, M. Wolfgarten, A. Sauerwald, M. Keyver-Paik, M. Kühr, R. Büttner, W. Kuhn  
Breast Cancer Res Treat (2008) 112:503–511

*Pre-operative staging of breast cancer with breast MRI: One step forward, two steps back?*  
C. K. Kuhl, W. Kuhn, M. Braun, H. Schild  
The Breast 2007 Oct 22 Volume 16, Issue 2, Supplement 1, 2007: 34-44

*Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer.*  
J.J. Hernando, T.-W. Park, H.P. Fischer, O. Zivanovic, M. Braun, M. Pölcher, U. Grunn, C. Leutner, B. Pötsch, W. Kuhn  
Lancet Oncology 2007 May; 8(5):451-454

*Treatment with Combinations of the Anti-HER2 Antibody Trastuzumab and Capecitabine in Advanced Metastatic Breast Cancer Patients – a Pilot Study.*  
M. Braun, B. Schlehe, A. Faridi, U. Heinrichs, C. Rudlowski  
Breast Care 2007;2:227-233

*Irradiated breast cancer patients demonstrate subgroup specific regularities in protein expression patterns of circulating leukocytes.*  
K. Yeghiazaryan, S. Mamlouk, D. Trog, H. Moenkemann, M. Braun, W. Kuhn, H. Schild, O. Golubnitschaja  
Cancer Genomics & Proteomics 2007 (4): 411-418

*The impact of the pathologist on the treatment of epithelial ovarian cancer.*  
O. Zivanovic, M. Braun, T.-W. Park, W. Kuhn  
Verh Dtsch Ges Pathol. 2005; 89:101-10

*Combination of B-mode and color Doppler sonography for differential diagnoses of breast lesions.*

M. Braun, M. Schelling, W. Kuhn, K. Ulm, S. Rutke, H. Graeff  
Geburtsh Frauenheilk 2001; 61: 2-6

*Combined Transvaginal B-Mode and Color Doppler Sonography for Differential Diagnosis of Ovarian Tumors: Results of a Multivariate Logistic Regression Analysis.*

M. Schelling, M. Braun, W. Kuhn, G. Bogner, R. Gruber, J. Gnirs, K.Th.M. Schneider, K. Ulm, S. Rutke, A. Staudach  
Gynecol Oncol. 2000 Apr;77(1):78-86

*Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer.*

A. Prechtel, N. Harbeck, C. Thomssen, C. Meisner, M. Braun, M. Untch, M. Wieland, B. Lisboa, T. Cufer, H. Graeff, K. Selbmann, M. Schmitt, F. Janicke  
Int J Biol Markers. 2000 Jan-Mar;15(1):73-8

*Optimized differential diagnosis of breast lesions by combined B-mode and color Doppler sonography.*

M. Schelling, J. Gnirs, M. Braun, R. Busch, S. Maurer, W. Kuhn, K.Th.M. Schneider, H. Graeff  
Ultrasound Obstet. Gynecol. 10 (1997): 48-53